XERS - Company ID 0001867096
Xeris Biopharma Holdings, Inc. trades as XERS and has a market capitalization of $1.44 B, making it the #2387 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $291.85M, up 43.7% from the prior year and net income of $554.00K. This page tracks Xeris Biopharma Holdings, Inc. through 290 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-11
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 5 fiscal years Xeris Biopharma Holdings, Inc.'s revenue grew from $20.43M to $291.85M, a compound annual growth rate of 70.2%. Net profit margin expanded from -446.0% to 0.2% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Quarterly report | 10-Q | 2026-05-07 |
| Major company event | 8-K | 2026-05-07 |
| Insider trade | 4 | 2026-05-01 |
| Annual report to shareholders | ARS | 2026-04-23 |
| Proxy materials | DEFA14A | 2026-04-23 |
| Proxy statement | DEF 14A | 2026-04-23 |
| Major company event | 8-K | 2026-04-21 |
| Insider trade | 4 | 2026-04-03 |
The largest companies sharing Xeris Biopharma Holdings, Inc.'s SEC industry classification (pharmaceutical preparations).
Xeris Biopharma Holdings, Inc. (XERS) has a market capitalization of $1.44 B as of 2026-07-11, ranking #2387 among US-listed companies.
Xeris Biopharma Holdings, Inc. reported revenue of $291.85M for fiscal year 2025, an increase of 43.7% year over year.
Yes. Xeris Biopharma Holdings, Inc. reported net income of $554.00K in its latest fiscal year.